|
|
|
Volumn 33 Suppl 3, Issue , 2009, Pages
|
|
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ANTIINFLAMMATORY AGENT;
ANTIMETABOLITE;
CERTOLIZUMAB PEGOL;
IMMUNOGLOBULIN F(AB) FRAGMENT;
IMMUNOSUPPRESSIVE AGENT;
INFLIXIMAB;
MACROGOL DERIVATIVE;
METHYLTRANSFERASE;
MONOCLONAL ANTIBODY;
THIOPURINE METHYLTRANSFERASE;
TUMOR NECROSIS FACTOR ALPHA;
ARTICLE;
CLINICAL TRIAL (TOPIC);
CROHN DISEASE;
DRUG ANTAGONISM;
DRUG COMBINATION;
DRUG INTERACTION;
ENTERITIS;
EVIDENCE BASED MEDICINE;
GENETICS;
HUMAN;
META ANALYSIS (TOPIC);
MONITORING;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REMISSION;
TREATMENT OUTCOME;
ULCERATIVE COLITIS;
ANTI-INFLAMMATORY AGENTS;
ANTIBODIES, MONOCLONAL;
ANTIMETABOLITES;
CLINICAL TRIALS AS TOPIC;
COLITIS, ULCERATIVE;
CROHN DISEASE;
DRUG INTERACTIONS;
DRUG THERAPY, COMBINATION;
EVIDENCE-BASED MEDICINE;
HUMANS;
IMMUNOGLOBULIN FAB FRAGMENTS;
IMMUNOSUPPRESSIVE AGENTS;
INFLAMMATORY BOWEL DISEASES;
META-ANALYSIS AS TOPIC;
METHYLTRANSFERASES;
MONITORING, PHYSIOLOGIC;
POLYETHYLENE GLYCOLS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
REMISSION INDUCTION;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 79952111959
PISSN: None
EISSN: 22107401
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|
